Triazole‐ and Imidazole‐Containing Compounds: Versatile VEGFR‐2 Inhibitors for Cancer Therapy
Vascular endothelial growth factor receptor 2 (VEGFR‐2) is a major mediator of pathological angiogenesis, which is critical to tumor progression and metastasis; therefore, inhibition of VEGFR‐2 remains a key therapeutic strategy for cancer. Despite the established clinical efficacy of several approved VEGFR‐2‐targeted...